Document is current
Any future updates will be listed below
-
Authors
Baltussen, Lucas L https://orcid.org/0000-0001-9742-6857
Negraes, Priscilla D https://orcid.org/0000-0001-7876-1895
Silvestre, Margaux https://orcid.org/0000-0003-1377-477X
Claxton, Suzanne
Moeskops, Max
Christodoulou, Evangelos https://orcid.org/0000-0001-8464-1558
Flynn, Helen R https://orcid.org/0000-0001-7002-9130
Snijders, Ambrosius P
Muotri, Alysson R https://orcid.org/0000-0003-0867-2875
Ultanir, Sila K https://orcid.org/0000-0001-5745-3957
-
Funding
Funding for this research was provided by:
Cancer Research UK (FC001201)
RCUK | Medical Research Council (FC001201)
Wellcome Trust (FC001201)
International Foundation for CDKL5 Research (FC001003)
International Foundation for CDKL5 Research (20152375)
Loulou Foundation (3823735)
Loulou Foundation (CDKL5‐17‐109‐01)
HHS | NIH | National Institute of Mental Health (R21MH10771)
- License Information
-
More Information
Article History
Received: 3 May 2018
Revised: 7 August 2018
Accepted: 31 August 2018
First Online: 28 September 2018
Conflict of interest
: A.R.M. is a co‐founder and has equity interest in TISMOO, a company dedicated to genetic analysis focusing on therapeutic applications customized for autism spectrum disorder and other neurological disorders with genetic origins. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict of interest policies.
